[{"id":"09e74a0b-2911-4165-9b8f-e77d19ed6b2f","acronym":"TroFuse-004","url":"https://clinicaltrials.gov/study/NCT06074588","created_at":"2023-10-10T14:11:53.919Z","updated_at":"2025-02-25T13:49:58.239Z","phase":"Phase 3","brief_title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","source_id_and_acronym":"NCT06074588 - TroFuse-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 556","initiation":"Initiation: 11/12/2023","start_date":" 11/12/2023","primary_txt":" Primary completion: 05/10/2027","primary_completion_date":" 05/10/2027","study_txt":" Completion: 03/11/2030","study_completion_date":" 03/11/2030","last_update_posted":"2025-02-20"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"c3e9ec33-9883-4e28-b473-f95df1486329","acronym":"Lung-Map Screening Study","url":"https://clinicaltrials.gov/study/NCT03851445","created_at":"2021-01-18T19:00:27.801Z","updated_at":"2025-02-25T14:07:20.756Z","phase":"Phase 2/3","brief_title":"Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03851445 - Lung-Map Screening Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 02/06/2019","start_date":" 02/06/2019","primary_txt":" Primary completion: 01/28/2029","primary_completion_date":" 01/28/2029","study_txt":" Completion: 01/28/2029","study_completion_date":" 01/28/2029","last_update_posted":"2025-02-17"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"961758d0-6679-4971-b806-6a0fe59d5b35","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05089916","created_at":"2021-10-22T12:53:07.379Z","updated_at":"2025-02-25T14:41:02.334Z","phase":"Phase 2","brief_title":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","source_id_and_acronym":"NCT05089916 - ROSE","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-14"},{"id":"f728f5a5-7b35-4430-bcb8-753e01deecd0","acronym":"ALCHEMIST","url":"https://clinicaltrials.gov/study/NCT02193282","created_at":"2021-01-18T10:14:33.510Z","updated_at":"2025-02-25T16:43:51.158Z","phase":"Phase 3","brief_title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","source_id_and_acronym":"NCT02193282 - ALCHEMIST","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 10/10/2026","primary_completion_date":" 10/10/2026","study_txt":" Completion: 10/10/2026","study_completion_date":" 10/10/2026","last_update_posted":"2025-02-06"},{"id":"b919dc89-9df8-4dbd-a935-be5a90714d37","acronym":"","url":"https://clinicaltrials.gov/study/NCT02279004","created_at":"2021-01-18T10:43:47.016Z","updated_at":"2025-02-25T16:43:52.535Z","phase":"","brief_title":"A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care","source_id_and_acronym":"NCT02279004","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • KRAS G12","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • KRAS G12"],"overall_status":"Recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 07/03/2014","start_date":" 07/03/2014","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-05"},{"id":"06aea852-4f4f-4fb7-987b-2400ee6b5c52","acronym":"ORBITAL","url":"https://clinicaltrials.gov/study/NCT04233021","created_at":"2021-01-18T20:35:29.375Z","updated_at":"2025-02-25T17:00:23.523Z","phase":"Phase 2","brief_title":"Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation","source_id_and_acronym":"NCT04233021 - ORBITAL","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/16/2020","start_date":" 07/16/2020","primary_txt":" Primary completion: 03/15/2023","primary_completion_date":" 03/15/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2025-02-03"},{"id":"0ce6edde-72a4-4b16-a147-428d02d9773d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433469","created_at":"2021-01-18T16:56:11.530Z","updated_at":"2025-02-25T14:58:42.444Z","phase":"Phase 2","brief_title":"Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery","source_id_and_acronym":"NCT03433469","lead_sponsor":"University of California, San Francisco","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/31/2018","start_date":" 07/31/2018","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-01-31"},{"id":"75b550a9-d016-442f-8549-62ab7dd6a2fd","acronym":"AZENT","url":"https://clinicaltrials.gov/study/NCT02841579","created_at":"2021-01-18T13:56:52.079Z","updated_at":"2025-02-25T15:07:10.729Z","phase":"Phase 2","brief_title":"Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M","source_id_and_acronym":"NCT02841579 - AZENT","lead_sponsor":"MedSIR","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/02/2016","start_date":" 09/02/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/14/2020","study_completion_date":" 02/14/2020","last_update_posted":"2025-01-28"},{"id":"4a460451-5964-49e7-8b50-20d79d3f9b89","acronym":"HEMONC CIRM IST Lung","url":"https://clinicaltrials.gov/study/NCT03546361","created_at":"2021-01-18T17:27:35.511Z","updated_at":"2025-02-25T16:07:56.707Z","phase":"Phase 1","brief_title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03546361 - HEMONC CIRM IST Lung","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ad-CCL21-DC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 01/11/2026","primary_completion_date":" 01/11/2026","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-01-14"},{"id":"248e13cf-d173-46ce-960b-a2537343cade","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573073","created_at":"2025-02-27T08:14:28.228Z","updated_at":"2025-02-27T08:14:28.228Z","phase":"","brief_title":"Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation","source_id_and_acronym":"NCT06573073","lead_sponsor":"LifeOS Genomics Corporation","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 09/06/2024","start_date":" 09/06/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-11-18"},{"id":"6abdabcb-20ec-463a-9da6-da3f3fef4258","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502330","created_at":"2021-01-18T17:14:06.052Z","updated_at":"2025-02-25T14:26:50.517Z","phase":"Phase 1","brief_title":"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03502330","lead_sponsor":"Yale University","biomarkers":" PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/09/2018","start_date":" 06/09/2018","primary_txt":" Primary completion: 01/05/2022","primary_completion_date":" 01/05/2022","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-07-03"},{"id":"229e5d3e-73c3-45a5-974b-b16c7567422e","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT05526755","created_at":"2022-09-02T17:00:16.764Z","updated_at":"2024-07-02T16:34:25.955Z","phase":"Phase 2","brief_title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","source_id_and_acronym":"NCT05526755 - TARGET","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 04/05/2029","primary_completion_date":" 04/05/2029","study_txt":" Completion: 04/05/2029","study_completion_date":" 04/05/2029","last_update_posted":"2024-06-14"},{"id":"23fc48e8-8769-4759-8eb9-b726dad67c99","acronym":"Lung-MAP Non-Matched Sub-Study","url":"https://clinicaltrials.gov/study/NCT03971474","created_at":"2021-01-18T19:32:15.856Z","updated_at":"2024-07-02T16:34:25.767Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","source_id_and_acronym":"NCT03971474 - Lung-MAP Non-Matched Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • lexatumumab (ETR2-ST01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 04/14/2022","primary_completion_date":" 04/14/2022","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-06-14"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"b148efd6-3461-4443-b111-648b5d1400c0","acronym":"ECOG-ACRIN LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT04625647","created_at":"2021-01-19T20:35:28.296Z","updated_at":"2024-07-02T16:34:27.131Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT04625647 - ECOG-ACRIN LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 04/16/2021","start_date":" 04/16/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-11"},{"id":"66566ad0-5762-43b1-aaba-eb5e68316afa","acronym":"NCI-2019-05913","url":"https://clinicaltrials.gov/study/NCT04085315","created_at":"2021-01-18T19:59:58.628Z","updated_at":"2024-07-02T16:34:36.874Z","phase":"Phase 1","brief_title":"Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer","source_id_and_acronym":"NCT04085315 - NCI-2019-05913","lead_sponsor":"Collin Blakely","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • alisertib (MLN8237)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/12/2019","start_date":" 11/12/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-10"},{"id":"46a2158d-7d81-48b2-9e8f-5fa40124c6d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02759835","created_at":"2021-01-18T13:32:03.544Z","updated_at":"2024-07-02T16:34:37.403Z","phase":"Phase 2","brief_title":"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib","source_id_and_acronym":"NCT02759835","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 04/13/2016","start_date":" 04/13/2016","primary_txt":" Primary completion: 05/25/2022","primary_completion_date":" 05/25/2022","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2024-06-07"},{"id":"13166d68-2e61-4c72-92f1-fac024df7835","acronym":"SAFFRON","url":"https://clinicaltrials.gov/study/NCT05261399","created_at":"2022-03-02T17:52:38.442Z","updated_at":"2024-07-02T16:34:59.035Z","phase":"Phase 3","brief_title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","source_id_and_acronym":"NCT05261399 - SAFFRON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/26/2025","primary_completion_date":" 06/26/2025","study_txt":" Completion: 12/17/2026","study_completion_date":" 12/17/2026","last_update_posted":"2024-06-04"},{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"ba697a0c-0213-4400-8a69-554239875d35","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04268550","created_at":"2021-01-18T14:26:41.644Z","updated_at":"2024-07-02T16:34:59.356Z","phase":"Phase 2","brief_title":"Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04268550 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-06-04"},{"id":"c4a67b85-d57e-45f1-9a88-e437704888be","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479306","created_at":"2021-01-18T21:30:41.583Z","updated_at":"2024-07-02T16:34:59.204Z","phase":"Phase 1","brief_title":"Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04479306","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 07/27/2023","primary_completion_date":" 07/27/2023","study_txt":" Completion: 07/27/2023","study_completion_date":" 07/27/2023","last_update_posted":"2024-06-04"},{"id":"626349ae-5e92-4b7b-935d-204508ea15b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05546866","created_at":"2022-09-21T21:57:03.169Z","updated_at":"2024-07-02T16:35:00.447Z","phase":"Phase 2","brief_title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","source_id_and_acronym":"NCT05546866","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2024-05-29"}]